Good morning and thank you all for being here.
The announcement we're making today is the culmination of months of hard work by the people at Texas A&M, their partners at GlaxoSmithKline, and years of dedication and investment on the state level.
Over the past decade, we've invested in innovative programs to prioritize research in our state, both at our universities and in the private sector.
Through tools like the Texas Emerging Technology Fund we've encouraged academic research and cutting-edge industries.
That's helped Texas vastly expand opportunities for those inspired and driven to create new treatments and new technologies.
Today Texas' workforce, talent, universities and business climate have made us a leader in high-tech innovation, research, development and commercialization.
In 2009, the state made a substantial ETF investment to create the National Center for Therapeutics Manufacturing at A&M.
That helped pave the way for last year's announcement that A&M would be home to one of three Centers for Innovation in Advanced Development and Manufacturing.
Today, we're taking it another step farther.
It's my pleasure to announce that Texas A&M has been selected for a cutting-edge vaccine manufacturing facility, a $91 million center that will help rapidly develop and manufacture vaccines to help combat influenza outbreaks.
Not only will this keep more Americans safer from epidemic, it will bring more than $41 billion in in-state expenditures over the next 25 years and directly and indirectly create more than 6,800 jobs in Texas.
It's fitting that this facility is coming here to Texas which is home to technological advancements that have shaped our nation, and our world, over the last century.
From oilfield innovations that unlocked the energy flowing beneath us to the development of the integrated circuit at Texas Instruments in the 1950s, and through the heart of the Space Race at NASA's Johnson Space Center, Texas is home to innovative minds and world-changing ideas.
Just recently, a pair of reports came out highlighting the thousands of clinical trials currently ongoing in Texas, with the National Institutes of Health ranking us second in the nation in 2012.
Whether in biotech, communications, commerce, or privatized efforts to serve the needs of the next generation of space explorers, you will find Texas at the forefront of the movement.
This new facility builds upon that tradition.
I congratulate everyone involved, and look forward to great things happening here in the decades to come.